Following the Trail of Evidence to Individualize and Optimize Multiple Sclerosis Care
SPONSORSHIP & SUPPORT
This educational activity is jointly provided by the Consortium of Multiple Sclerosis Centers and International Organization of Multiple Sclerosis Nurses and Spire Learning.
This activity is supported by an educational grant from Genentech, a member of the Roche Group
Multiple sclerosis (MS) is a chronic neurodegenerative autoimmune disease with a complex clinical course characterized by inflammation, demyelination, and axonal degeneration. Early diagnosis, early aggressive treatment, and monitoring of disease progression have emerged as key principles of effective MS management. The ever-expanding volume of clinical trial data and variations in the clinical endpoints have complicated therapeutic decision making. An optimal treatment is usually based on a personalized approach determined by an individual patient’s prognosis and treatment risks. Furthermore, current evidence is progressing to advance understanding of the role of biomarkers in early diagnosis, predicting disease progression, and assessing response to MS treatment.
This multidisciplinary educational initiative is targeted to clinicians who care for people with MS including neurologists, nurses, nurse practitioners, physician assistants, and pharmacists.
ACCREDITATION AND CREDIT DESIGNATION
In support of improving patient care, this activity has been planned and implemented by the Consortium of Multiple Sclerosis Centers (CMSC) and Spire Learning. CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians: The CMSC designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses: This activity is awarded 2.0 contact hours of continuing nursing education credits (2.0 in the area of pharmacology).
Pharmacists: This knowledge-based activity, UAN # JA4008165-9999-20-036-H01-P, qualifies for 2.0 contact hours (.2 CEUs) of continuing pharmacy education credit.
Upon successful completion of the activity, your CE credits will be submitted electronically to the NABP CPE Monitor service. For information about CPE Monitor, visit https://nabp.pharmacy/cpe-monitor-service/
Paper certificates are not valid for pharmacy credit.
INSTRUCTIONS ON HOW TO RECEIVE CREDIT
There is no fee to participate in this activity. In order to receive CME/CE credit, you must complete:
- Baseline Assessment
- Modules 1,2, and 3
- Final Assessment
- Activity Evaluation
Your certificate can be printed immediately.
CMSC and Spire Learning present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. CMSC, IOMSN, Spire Learning, and the commercial supporters assume no liability for the information herein.
Copyright © 2020 by Spire Learning, LLC and its Licensors. All rights reserved. No part of this publication or activity may be reproduced or transmitted in any form, by any means, without prior written permission of Spire Learning, LLC. Spire Learning, LLC and CMSC will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication or activity, including any claims related to the products, drugs, or services mentioned herein.
LEVELS OF EVIDENCE
Level of evidence and obligation were assessed by the American Academy of Neurology (AAN) guidelines using a Delphi process and assigning the following scores:
Level A is the strongest recommendation level and is denoted by use of the helping verb must. These recommendations are rare, as they are based on high confidence in the evidence and require both a high magnitude of benefit and low risk
• Must (not) prescribe, offer (treatment); Must (not) test, counsel, monitor (screen, diagnose); Must avoid (causation)
Level B corresponds to the helping verb should. Such recommendations are more common, as the requirements are less stringent but still based on the evidence and benefit−risk profile
• Should (not) offer, prescribe; Should (not) test, counsel, monitor; Should avoid
Level C, which corresponds to the helping verb may, represents the lowest allowable recommendation level the AAN considers useful within the scope of clinical practice and can accommodate the highest degree of practice variation
• May offer, prescribe; May test, counsel, monitor, educate; May avoid; May choose not to offer, prescribe; May choose not to test, counsel, monitor
This educational activity may contain discussion of published and/or investigational uses of therapies that are not indicated by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, participants are encouraged to consult appropriate resources for any product or device mentioned in this program.
CONFLICT OF INTEREST STATEMENT
According to the disclosure policy of the CMSC, all faculty, planning committee members, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships alone is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence.
Spire Learning, LLC is committed to protecting the privacy of personal information from our participants and educational collaborators. Spire maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of personal information.
Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing an activity. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of each activity. All evaluative information submitted is collected and retained, and used by Spire Learning, LLC to continuously improve the learning experience.
Spire Learning, LLC will not transfer, sell, or share personal information with outside parties or otherwise disclose personal information unless required to in a legal process. Spire will retain your personal data only for the period necessary to accomplish the stated purposes and to comply with applicable laws.
EDUCATIONAL PLANNING COMMITTEE
Consortium of Multiple Sclerosis Centers (CMSC)
June Halper, MSN, APN-C, MSCN, FAAN, Chief Executive Officer has disclosed no relevant financial relationships with any commercial interests.
Shareholder (spouse/partner): Johnson & Johnson
Employee (spouse/partner): Novo Nordisk
Chris Washburn, PhD
Employee (spouse/partner): Janssen Pharmaceuticals, Inc
Lisa Colombo has disclosed no relevant financial relationships with any commercial interests.
Contact Information: If you have any questions relating to the accreditation of this activity, please contact Lisa Colombo, Spire Learning, email@example.com
All planning committee members also served as reviewers.
June Halper, MSN, APN-C, MSCN, FAAN
CEO, Consortium of Multiple Sclerosis Centers
Laurie Scudder, DNP, NP, served as a planner and reviewer for this activity. She has disclosed no relevant financial relationships.
All other CMSC and Spire staff who are in a position to influence content have disclosed no relevant financial relationships.
Edward Fox, MD, PhD, FAAN
Director, MS Clinic of Central Texas
Central Texas Neurology Consultants, PA
Clinical Associate Professor of Neurology
University of Texas Dell Medical School
Round Rock, TX
Advisory Board – for marketing purposes: Biogen Inc; EMD Serono, Inc; Genentech, Inc; Novartis; Roche
Advisory Board – for scientific information: Biogen Inc; Celgene Corp; EMD Serono, Inc; Genentech, Inc; Novartis; Roche
Consultant – for marketing purposes: Biogen Inc; EMD Serono, Inc; Genentech, Inc; Novartis; Roche
Consultant – for clinical trial design: Biogen Inc; Celgene Corp; EMD Serono, Inc; Genentech, Inc; Novartis; Roche
Grant Recipient/Research Support: Biogen Inc; Celgene Corp; Chugai Pharmaceutical Co; EMD Serono, Inc; Genentech, Inc; MedDay Pharmaceuticals; Novartis; Roche; Sanofi Genzyme; TG Therapeutics, Inc
Speaker’s Bureau: Biogen Inc; EMD Serono, Inc; Genentech, Inc; Novartis; Roche; Sanofi Genzyme; Teva Pharmaceuticals
Stephanie A. Agrella, PhDc, MSN, RN, ANP-BC, MSCN
Director of Clinical Services
Multiple Sclerosis Clinic of Central Texas
Round Rock, TX
Consulting Fees: Biogen Inc; Bristol Myers Squibb; EMD Serono, Inc; Genentech, Inc; Genzyme
Speaker’s Bureau: Biogen, Inc; Bristol Myers Squibb; EMD Serono, Inc; Genentech, Inc; Genzyme; Novartis; Viela Bio
Jacquelyn L. Bainbridge, BSPharm, PharmD, FCCP, MSCS, FAES
Professor, Department of Clinical Pharmacy
Skaggs School of Pharmacy and Pharmaceutical Sciences
Professor, Department of Neurology
Anschutz Medical Campus
University of Colorado
Advisory Board: Genentech, Inc